These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32124728)

  • 1. Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study.
    Diaz C; Koren M; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Febo I; Vaughn DW; Wilson TM; Paris RM; Schmidt AC; Thomas SJ
    Am J Trop Med Hyg; 2020 May; 102(5):951-954. PubMed ID: 32124728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
    Diaz C; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Toussaint JF; Febo I; Innis BL; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2018 May; 98(5):1435-1443. PubMed ID: 29512481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Immunogenicity of an AS03
    Lin L; Lyke KE; Koren M; Jarman RG; Eckels KH; Lepine E; McArthur MA; Currier JR; Friberg H; Moris P; Keiser PB; De La Barrera R; Vaughn DW; Paris RM; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2020 Jul; 103(1):132-141. PubMed ID: 32342848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States.
    Schmidt AC; Lin L; Martinez LJ; Ruck RC; Eckels KH; Collard A; De La Barrera R; Paolino KM; Toussaint JF; Lepine E; Innis BL; Jarman RG; Thomas SJ
    Am J Trop Med Hyg; 2017 Jun; 96(6):1325-1337. PubMed ID: 28719287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
    Bauer K; Esquilin IO; Cornier AS; Thomas SJ; Quintero Del Rio AI; Bertran-Pasarell J; Morales Ramirez JO; Diaz C; Carlo S; Eckels KH; Tournay E; Toussaint JF; De La Barrera R; Fernandez S; Lyons A; Sun W; Innis BL
    Am J Trop Med Hyg; 2015 Sep; 93(3):441-453. PubMed ID: 26175027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.
    Martinez LJ; Lin L; Blaylock JM; Lyons AG; Bauer KM; De La Barrera R; Simmons M; Jarman RG; Currier JR; Friberg H; Danko JR; Teneza-Mora NC; Putnak JR; Eckels KH; Thomas SJ
    Am J Trop Med Hyg; 2015 Sep; 93(3):454-460. PubMed ID: 26149862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
    Moris P; Bauer KM; Currier JR; Friberg H; Eckels KH; Esquilin IO; Gibbons RV; Innis BL; Jarman RG; Simasathien S; Sun P; Thomas SJ; Watanaveeradej V
    Hum Vaccin Immunother; 2019; 15(9):2090-2105. PubMed ID: 30829100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.
    Manoff SB; Sausser M; Falk Russell A; Martin J; Radley D; Hyatt D; Roberts CC; Lickliter J; Krishnarajah J; Bett A; Dubey S; Finn T; Coller BA
    Hum Vaccin Immunother; 2019; 15(9):2195-2204. PubMed ID: 30427741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
    Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.
    Watanaveeradej V; Gibbons RV; Simasathien S; Nisalak A; Jarman RG; Kerdpanich A; Tournay E; De La Barrerra R; Dessy F; Toussaint JF; Eckels KH; Thomas SJ; Innis BL
    Am J Trop Med Hyg; 2014 Jul; 91(1):119-28. PubMed ID: 24865677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
    Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.
    Fernandez S; Thomas SJ; De La Barrera R; Im-Erbsin R; Jarman RG; Baras B; Toussaint JF; Mossman S; Innis BL; Schmidt A; Malice MP; Festraets P; Warter L; Putnak JR; Eckels KH
    Am J Trop Med Hyg; 2015 Apr; 92(4):698-708. PubMed ID: 25646261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.
    Thomas SJ; Eckels KH; Carletti I; De La Barrera R; Dessy F; Fernandez S; Putnak R; Toussaint JF; Sun W; Bauer K; Gibbons RV; Innis BL
    Am J Trop Med Hyg; 2013 Jan; 88(1):73-88. PubMed ID: 23208878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.